Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTESSA 2: Tesetaxel + Capecitabine in Taxane-Naive MBC
NCT03858972Phase 2Terminated
- Sponsor
- Odonate Therapeutics
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of tesetaxel in breast cancer, sponsored by Odonate Therapeutics. Primary endpoint: Objective Response Rate. Started Feb 2019; status: terminated.
02
Drugs
tesetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03858972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858972.